Octave Bioscience Is Hiring a Commercial Team. The Harder Part Comes Next.

Octave Bioscience just hired its third senior commercial executive in eight months. Kirk Stockwood as SVP of Commercial in January. Zachary Fernandes as VP of Business Development in May. Jennifer Mellum as VP of Marketing yesterday.

The press release calls it scaling. The more interesting question is what kind of problem you need three commercial leaders to solve — and what happens when the product isn't being used widely enough to justify them.

Octave is a private company founded in 2014 that sells a blood test for multiple sclerosis. The Octave MSDA Test measures 18 protein biomarkers across four biological domains and produces a single score from 1 to 10 telling neurologists whether a patient's MS is actively inflaming. It was the first blood test of its kind for MS. found the test outperformed neurofilament light alone — the single biomarker most neurologists currently watch — in detecting active inflammatory disease.

The test is FDA-cleared and CLIA-certified. It's reimbursed by multiple payers, including Aetna and UnitedHealthcare, which have coverage policies for it. Since December 2025, patients have been able to get blood drawn at Quest Diagnostics' network of roughly 7,000 collection sites across the United States.

On paper, nothing is missing. The product exists. The validation exists. The distribution exists. The reimbursement exists.

So why are they still hiring commercial leaders?

The answer is in the numbers they don't usually lead with. Octave reported $19.1 million in revenue in 2023, with a team of 113 people at the time. For a diagnostic test with a potentially huge addressable market — roughly 926,000 diagnosed MS patients in the United States — $19 million is proof that the test works, not proof that it scales. If every patient with MS were tested once a year at the implied per-test price, that's a multi-billion-dollar market. Octave captured a fraction of a fraction.

The company has raised $14 million in Series A, $32 million in Series B, and $35.6 million in Series C equity — about $82 million in venture capital — plus a $15.5 million term loan announced alongside the Series C. The Series C closed in September 2025, a full year ago. Private diagnostic companies at this stage typically have 18 to 24 months of runway after a Series C, depending on burn. Octave has roughly 89 employees now and a growing commercial organization. The next financing decision — whether to raise again, go public, or seek a strategic buyer — is probably approaching.

The investors include Novartis and Merck's Global Health Innovation Fund. These are sophisticated backers who care about the science. What they need now is proof that the commercial machine can run without constant outside capital.

The way to think about this is to ask what each new hire is supposed to fix. Kirk Stockwood, coming from Quanterix where he led neurology and immunology sales, is supposed to build the field force and expand the number of doctors ordering the test. Zachary Fernandes is supposed to lock in partnerships that make Octave tests the default option at hospital systems and pharma companies. Jennifer Mellum, with a background spanning Clorox, GRAIL, and Prime Therapeutics, is supposed to create demand and make the test a routine part of MS care.

Sales people orders. Business development builds infrastructure. Marketing builds awareness. This is the classic order for scaling a specialty diagnostic — and the order matters because you can't ask doctors to order something patients haven't heard of, but you also can't build a brand around something that hasn't been proven at scale.

The bottleneck might not be awareness at all. It might be that neurologists simply haven't felt the need to add a new blood test to their existing workflow. MS is managed with MRIs, clinical exams, and increasingly with neurofilament light — a simpler biomarker that measures one protein instead of 18. The Octave test is better. The published research says so. But better doesn't always mean adopted, especially when it requires changing the monitoring rhythm doctors have used for decades.

In that scenario, the commercial team isn't a growth engine. It's a bet on persuasion.

For an investor who might eventually own shares in this company — through an IPO, a secondary offering, or a strategic acquisition — the question becomes: can Octave convert its roughly $97 million in total capital, its Quest partnership, and its clinical validation into a commercial motion that works?

One concrete thing to watch: revenue growth. $19.1 million in 2023 is the last figure that's been publicly disclosed. If that number grows into the tens of millions over the next 12 months, the commercial hires are working. If it stays in the same range, the bottleneck is deeper than awareness, and the company will need a different explanation for why the test that clearly works hasn't moved the needle.

The other thing to watch is the next financing move. A year after the Series C, capital is probably getting tight. Octave has options — a later-stage private round, an IPO, or a strategic buyer in diagnostics or pharma. Each outcome means something different for the value of the shares. But all of them require the same thing: evidence that the current revenue is a beginning, not a ceiling.

The hiring isn't the story. The hiring is a signal that the company believes the story is about to change. Whether it does is a question the next batch of revenue numbers will answer.